Cargando…

Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients

PURPOSE: The once daily formulation of tacrolimus is an important immunosuppressive drug. Interpatient variability in metabolism has been related to genetic variation in CYP3A4 and CYP3A5. However, in liver transplantation, both donor and recipient genotypes may affect pharmacokinetics. The primary...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moes, D. J. A. R, van der Bent, S. A. S, Swen, J. J., van der Straaten, T., Inderson, A., Olofsen, E., Verspaget, H. W., Guchelaar, H. J., den Hartigh, J., van Hoek, B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Pharmacogenetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4713720/ https://www.ncbi.nlm.nih.gov/pubmed/26521259 http://dx.doi.org/10.1007/s00228-015-1963-3

Ejemplares similares

Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19
por: Swen, J. J., et al.
Publicado: (2011)

Explaining variability in ciclosporin exposure in adult kidney transplant recipients
por: Press, Rogier R., et al.
Publicado: (2010)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
por: Sanchez Spitman, A. B., et al.
Publicado: (2017)

Medical education in pharmacogenomics—results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx)
por: Just, Katja Susanne, et al.
Publicado: (2017)

The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation
por: de Wildt, Saskia N., et al.
Publicado: (2011)

The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
por: Lunde, Ingrid, et al.
Publicado: (2014)

Non-response to (statin) therapy: the importance of distinguishing non-responders from non-adherers in pharmacogenetic studies
por: Trompet, S., et al.
Publicado: (2015)

Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma
por: Diekstra, Meta H. M., et al.
Publicado: (2015)

The influence of recipient SLCO1B1 rs2291075 polymorphism on tacrolimus dose–corrected trough concentration in the early period after liver transplantation
por: Wu, Yi, et al.
Publicado: (2021)

Warfarin dose prediction in children using pharmacometric bridging—comparison with published pharmacogenetic dosing algorithms
por: Hamberg, Anna-Karin, et al.
Publicado: (2013)

Man vs. machine: comparison of pharmacogenetic expert counselling with a clinical medication support system in a study with 200 genotyped patients
por: Preissner, Sally H., et al.
Publicado: (2021)

Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice
por: Russmann, Stefan, et al.
Publicado: (2020)

Analysis of common type 2 diabetes mellitus genetic risk factors in new-onset diabetes after transplantation in kidney transplant patients medicated with tacrolimus
por: Kurzawski, Mateusz, et al.
Publicado: (2012)

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy
por: Azuma, Junichi, et al.
Publicado: (2012)

Electronic health records for biological sample collection: feasibility study of statin-induced myopathy using the Clinical Practice Research Datalink
por: O'Meara, Helen, et al.
Publicado: (2014)

Comparison of the Impact of Pharmacogenetic Variability on the PK of Slow Release and Immediate Release Tacrolimus Formulations
por: van Gelder, Teun, et al.
Publicado: (2020)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation
por: Moes, D J A R, et al.
Publicado: (2014)

Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters
por: Geisen, Christof, et al.
Publicado: (2010)

Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide
por: Dziedziejko, Violetta, et al.
Publicado: (2011)

Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study
por: Andreassen, Trine Naalsund, et al.
Publicado: (2011)

Effect of the ADRB1 1165C>G and 145A>G polymorphisms on hemodynamic response during dobutamine stress echocardiography
por: Banaś, Anna, et al.
Publicado: (2011)

CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers
por: Gawrońska-Szklarz, Barbara, et al.
Publicado: (2012)

Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan
por: Shimazawa, R, et al.
Publicado: (2014)

In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics
por: Jin, Yi, et al.
Publicado: (2017)

No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA
por: Vizeli, Patrick, et al.
Publicado: (2017)

N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians
por: Aklillu, Eleni, et al.
Publicado: (2018)

Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin
por: Mugusi, Sabina, et al.
Publicado: (2018)

The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients
por: Wattanachai, Nitsupa, et al.
Publicado: (2017)

Lack of association between CYB5A gene rs1790834 polymorphism and the response to leflunomide in women with rheumatoid arthritis
por: Łączna, Małgorzata, et al.
Publicado: (2021)

The association of GATM polymorphism with statin-induced myopathy: a systematic review and meta-analysis
por: Liu, Mengyuan, et al.
Publicado: (2020)

Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients
por: Martial, Lisa C., et al.
Publicado: (2021)

Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing
por: Yin, Anyue, et al.
Publicado: (2020)

The Clinical Impact of the C(0)/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients
por: van Gelder, Teun, et al.
Publicado: (2020)

Pharmacogenetics in the clinic
por: Guchelaar, H.-J.
Publicado: (2013)

Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact
por: van der Wouden, Cathelijne H., et al.
Publicado: (2019)

Influence of Glutathione-S-Transferase A1*B Allele on the Metabolism of the Aromatase Inhibitor, Exemestane, in Human Liver Cytosols and in Patients Treated With Exemestane
por: Teslenko, Irina, et al.
Publicado: (2022)

The Pharmacogenetics of Tacrolimus in Corticosteroid-Sparse Pediatric and Adult Kidney Transplant Recipients
por: Madsen, Mads Juul, et al.
Publicado: (2017)

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib
por: Steeghs, Neeltje, et al.
Publicado: (2010)

Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease
por: Bangma, Amber, et al.
Publicado: (2020)

Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands
por: Bank, P. C. D., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m6guaaf38h5t6ospahqk7im6tk